Medical Policy Updates

Home ❯ Providers ❯ Medical Policies and Coverage ❯ Back to Medical Policy Updates ❯ Blue Cross and Blue Shield of North Carolina Medical Policy Update January 12, 2021

Medical Policy Update for January 12, 2021

Medical Guidelines Reason for Update
Atezolizumab (Tecentriq) for Intravenous Use Updated "When Covered" section with the following indications: metastatic NSCLC with no EGFR or ALK genomic tumor aberrations and whose tumors have high PD-L1 expression as determined by an FDA-approved test, and are receiving atezolizumab as first-line treatment; metastatic NSCLC with no EGFR or ALK genomic tumor aberrations, and are receiving atezolizumab as first-line treatment in combination with paclitaxel protein-bound and carboplatin; unresectable or metastatic HCC with no prior systemic chemotherapy; and BRAF V600 mutation-positive unresectable or metastatic melanoma. Updated Policy Guidelines with appropriate dosing by indication. Minor edits made throughout policy for clarity. Reference added. Specialty Matched Consultant Advisory Panel review 11/18/2020.
Blinatumomab (Blincyto®) Specialty Matched Consultant Advisory Panel review 11/18/2020. No change to policy intent.
Copanlisib (Aliqopa™) Specialty Matched Consultant Advisory Panel review 11/18/2020. No change to policy intent.
Daunorubicin and Cytarabine (Vyxeos™) Specialty Matched Consultant Advisory Panel review 11/18/2020. No change to policy intent.
Enfortumab vedotin-ejfv (Padcev™) Specialty Matched Consultant Advisory Panel review 11/18/2020. No change to policy statements.
Genetic Testing for Neurodegenerative Disorders AHS – M2167 New policy developed. Genetic testing for neurodegenerative disorders is covered when coverage criteria are met. Notification given 11/10/2020 for policy effective date 01/12/2021.
Injection Therapy for Headache (Migraine and Other) and Non-Spine Management Specialty Matched Consultant Advisory Panel review 10/21/2020. ICD-10 diagnosis codes from M16 series, M17 series, M19 series, and M25 series removed from Billing/Coding section.
Inotuzumab (Besponsa®) Specialty Matched Consultant Advisory Panel review 11/18/2020. No change to policy intent.
Luspatercept-aamt (Reblozyl®) Specialty Matched Consultant Advisory Panel review 11/18/2020. No change to policy statements.
Olaratumab (Lartruvo™) Specialty Matched Consultant Advisory Panel review 11/18/2020. No change to policy intent.
Rituximab for the Treatment of Rheumatoid Arthritis Under "When Covered" for Rituxan (rituximab), added additional biosimilar, Riabni (rituximab-arrx), with same indications and coverage criteria as Rituxan (rituximab). Reference added. Medical Director review 1/2021.
Romiplostim (NPlate) Specialty Matched Consultant Advisory Panel 11/18/2020. No change to policy intent.